Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 3/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | GLB1 | P16278 | 4/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7999790 | 1.00 | HDAC6 (1.00) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL8021912 | 1.00 | HDAC6 (1.00) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL8018886 | 0.99 | HDAC6 (0.98) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL15515613 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL15507473 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL8016351 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL591663 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL15515796 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL18257191 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 | |
| SCHEMBL15259321 | 0.88 | HDAC4 (0.79) | HDAC6HDAC4HDAC10HDAC5GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293513-B2 | Histone deacetylase inhibitors | GEORGETOWN UNIVERSITY (US) | 2012-10-23 | — | — | US | claimed |
| CN-101970399-A | Histone deacetylase inhibitors | UNIV GEORGETOWN | 2011-02-09 | — | — | CN | claimed |
| US-20100317739-A1 | HISTONE DEACETYLASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | claimed |
| EP-2231596-A1 | HISTONE DEACETYLASE INHIBITORS | Georgetown University (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009079375-A1 | HISTONE DEACETYLASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | WO | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-8293513-B2 | Histone deacetylase inhibitors | GEORGETOWN UNIVERSITY (US) | 2012-10-23 | — | — | US | disclosed |
| CN-101970399-A | Histone deacetylase inhibitors | UNIV GEORGETOWN | 2011-02-09 | — | — | CN | disclosed |
| US-20100317739-A1 | HISTONE DEACETYLASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| EP-2231596-A1 | HISTONE DEACETYLASE INHIBITORS | Georgetown University (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009079375-A1 | HISTONE DEACETYLASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009079375-A1 | HISTONE DEACETYLASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HDAC6 898/4885HDAC4 2320/4885HDAC10 1110/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC6 1477/4885HDAC4 2054/4885HDAC10 783/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC6 1477/4885HDAC4 2054/4885HDAC10 783/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | HDAC6 716/4885HDAC4 2401/4885HDAC10 834/4885 |
| US-20100317739-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC6 10/4885HDAC4 8/4885HDAC10 11/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HDAC6 645/4885HDAC4 785/4885HDAC10 408/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | HDAC6 357/4885HDAC4 1375/4885HDAC10 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.